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The roots of yellow gentian, Gentiana lutea L. (Gentianaceae) are used in traditional medicine for the
treatment of gastrointestinal disorders, with the literature data indicate a local gastric effect of gen-
tian root extract (GRE) and support the use of the solid pharmaceutical forms. Gentiopicroside, as a
dominant secoiridoid in the GRE, has a short elimination half-life and low bioavailability and, conse-
quently, its bioactivity is limited. The aim of the study was to develop gastroretentive floating deliv-
ery system with GRE, and to provide prolonged release of gentiopicroside. Floating granules with dry
GRE (DGRE) were prepared by the hot-melt granulation technique, while formulations included ef-
fervescent components (citric acid and sodium bicarbonate), hydroxypropyl methylcellulose (HPMC)
and meltable binders (Compritol® 888 ATO and Gelucire® 50/13). The flowability of the DGRE and
prepared formulations was determined by calculating the Carr index and Hausner ratio. Floating
properties and in vitro dissolution rate of gentiopicroside from investigated formulations were exam-
ined. Floating granules were characterized with improved flowability (Carr index 14-22 %; Hausner
ratio 1.16-1.28) in comparison to the DGRE (Carr index 28.99 %; Hausner ratio of 1.41). Furthermore,
the floating granules exhibited immediate and long-lasting buoyancy and prolonged-release of gen-
tiopicroside (over 8 h). Compritol® 888 ATO has provided sustained release of gentiopicroside from
floating granules, while HPMC has decreased release rate additionally. On the other hand, Gelucire®
50/13 has increased gentiopicroside release rate. The results have shown that hot-melt granulation
technique, as a green granulation method was successfully employed for obtaining gastroretentive
floating granules with DGRE.
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1. INTRODUCTION
Underground parts of yellow gentian, Gentiana lutea L. (Gen-
tianaceae) are used in traditional medicine for the treatment
of gastrointestinal disorders, such as dyspepsia, liver dysfunc-
tion, loss of appetite, while it is official in the European and
many nationals Pharmacopoeias (Šavikin et al., 2015; Ph. Eur.
10.0, 2020). Previous studies have shown choleretic (Öztürk
et al., 2002), anti-inflamtory (Mathew et al., 2004), antiulcero-
genic (Niiho et al., 2006), radioprotective (Menković et al.,
2010), analgesic (Öztürk et al., 2002) and antimicrobial (Pontus
et al., 2006) activity of gentian root extract. Beneficial health
effects of gentian root extract are associated with the pres-
ence of bitter-tasting secoiridoids (gentiopicroside, sweroside,
swertiamarin, loganic acid) and biphenyl derivatives (amaro-
gentin, amaropanin and amaroswerin), as well as phenolics i.e.
xanthones (isogentisin, gentioside, gentisin), and flavonoids
(isovitexin, isoorientin) (Šavikin et al., 2015; Živković et al.,
2019). Gentiopicroside is the dominant bioactive compound
in the gentian root extract with choleretic, hepatoprotective,
adaptogenic and anti-inflammatory activities (Wu et al., 2017).
However, there are obstacles, due to suboptimal pharmacoki-
netic properties of gentiopicroside, such as short elimination
half-life (2.8 h) and low bioavailability (39.6 %), reported after
animal studies (Wang et al., 2004) that limit its bioactive poten-
tial. Therefore, there is a need to formulate delivery systems
with prolonged release of gentian root extract. Furthermore,
the literature data indicate a local gastric effect of gentian root
extract and support the use of the solid pharmaceutical forms
(EMA, 2018).
Gastroretentive delivery systems are designed to provide pro-
longed residence time in the stomach as well as controlled
release of active compounds. Such systems are suitable for
active compounds with the local effect in the stomach, short
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elimination half-life, higher absorption in the upper part of the
gastrointestinal tract or in the case of active compounds insta-
bility in the intestine at higher pH (Lopes et al., 2016; Tripathi
et al., 2019). Shah et al. (2009) have reviewed gastroretentive
floating delivery systems for Helicobacter pylori eradication
with herbal drugs. In addition, Prasanthi (2019) has presented
gastroretentive tablets of Coccinia grandis leaf extract for treat-
ing H. pylori infection. Zhang et al. (2018) have demonstrated
enhanced gastric therapeutic effects of Brucea javanica oil for-
mulated in a gastrorentive delivery system, compared to the
commercial products. Kim et al. (2017) have demonstrated, in
in vivo studies, the gastroprotective effects of Artemisia princeps
gastroretentive floating tablets. Efficient antiulcer gastroreten-
tive systems have been developed for Boswellia oleogum resin
(Yusif et al., 2016) and aspen bark dry extract (Krylova et al.,
2018).
Floating drug delivery systems are gastroretentive delivery
systems with lower density compared to the gastric fluid
(1.004 g/cm3) (Tripathi et al., 2019). Therefore, these sys-
tems float on the surface of the gastric fluid and remain in
the stomach longer, while the active principles are released
from the system at the desired, modified rate. Multiple-unit
gastroretentive delivery systems, such as floating granules
have been proposed to overcome the risk of losing effect too
early due to “all-or-none“ emptying from the stomach related
to single-unit dosage forms (Mishra and Dhole, 2019; Zhai
et al., 2014). The hot-melt granulation technique is recognized
as an environmentally-friendly solvent-free green method that
can be utilized for the preparation of gastroretentive floating
delivery systems (Aoki et al., 2015; Khaled et al., 2020; Shimpi
et al., 2004; Zhai et al., 2014). Futhermore, meltable binders
that enable the hot-melt granulation, may also sustain the ac-
tive ingredients release rate and provide floating due to the
hydrophobic nature (Patel et al., 2018).
There is an unmet need in developing formulations with gen-
tian root extract that could stay in the stomach, as the targeted
site of action, for prolonged periods of time. The development
of gastroretentive formulations is considered as a viable ap-
proach that could lead to an increase in the therapeutic efficacy
and reduction in the dosing frequency. Therefore, the aim of
the presented study was to develop gastroretentive floating
delivery system, by using the hot-melt granulation technique,
and to provide prolonged release of active compounds from
gentian root extract. Gentiopicroside, selected as a marker
compound, is expected to be released in a continuous man-
ner. The effect of lipid excipients (Compritol® 888 ATO and
Gelucire® 50/13) and hydrophilic polymer (hydroxypropyl
methylcellulose) on flowability, floating time and gentiopicro-
side release rate was investigated.
2. MATERIALS AND METHODS
2.1. Plant material and chemicals
Excipients used for formulation were hydroxypropyl methyl-
cellulose (HPMC, Methocel® E5 LV, Dow®, USA), hydrophilic
polymer used as a matrix forming excipient, lactose monohy-
drate was used as a diluent, citric acid and sodium bicarbon-
ate as an effervescent components, while glyceryl behenate
(Compritol® 888 ATO, Gattefrosse, Saint-priest, Cedex, France)
and stearoyl macrogol-32 glycerides (Gelucire® 50/13, Gat-
tefrosse, Saint-priest, Cedex, France) were used as meltable
binders. Ethanol 96 % (v/v) (Honeywell Riedel de Haën,
Seelze, Germany), orthophosphoric acid (Sigma–Aldrich
Chemie GmbH, Münich, Germany), acetonitrile (Merck, Ger-
many) was HPLC grade and ultra-pure water was prepared
using a Milli-Q purification system (Millipore, France). Gen-
tiopicroside (ChromaDex, USA) standard was used. All excip-
ients, reagents and standards used were of analytical grade.
2.2. Preparation of dry extract
Plant material, Gentiana lutea roots, was purchased from the
Institute for Medicinal Plants Research “Dr. Josif Pančić“
(Belgrade, Serbia). Liquid gentian root extract was obtained
by heat-assisted extraction under the optimal conditions de-
scribed by Mudrić et al. (2020). Extraction in a thermostated
water bath (Grant, model LSB 18, United Kingdom) lasted 129
minutes, at a temperature of 65 °C, ethanol concentration was
49 % and the solid-to-solvent ratio was 1:40. After filtration,
the liquid extract was dried in a laboratory spray dryer. The
inlet temperature was 95 °C, the outlet temperatures varied
between 50-70 °C, the feed flow rate of the extract was 22 rpm.
Obtained dry gentian root extract was used in all prepared
formulations.
2.3. Preparation of formulations
Five formulations were prepared according to the Table 1.
Physical mixture of powders (formulation A) was prepared
by mixing of dry gentian root extract, lactose monohydrate,
HPMC, effervescent components (citric acid and sodium bi-
carbonate) according to the principle of compound powder
production. Formulations B, C, D and E and were prepared
by the hot-melt granulation. Powder mixture was added to
melted binder (Compritol® or mixture of Compritol® and
Gelucire® 50/13) at a temperature of 75 °C ± 2 °C, with con-
tinuous stirring. After cooling, obtained mass was crushed,
with a mortar and pestle and granulate was sieved through a
250 µm sieve.
2.4. Micromeritic properties
Bulk density was determined by measuring the mass of a
known volume of powder in a beaker. Tapped density was
determined in a vibrating volumeter (Stampfvolumeter STAV
2003, Jel, Germany). Based on the data on bulk and tapped
density, it is possible to define the flowability of granules by
calculating Carr index and Hausner ratio as follows:
Carr index (%) =






The powder/granules flow classification was performed ac-
cording to the European Pharmacopoeia 10.0 (Ph. Eur. 10.0,
2020).
2.5. Floating investigation
Formulations A, B, C, D and E were placed in 500 mL (37
°C ± 0.5 °C) of 0.1 M HCl (pH=1.2) in the type II dissolution
apparatus (apparatus with rotating paddle, Erweka DT600,
Germany). The medium was agitated by paddle at 50 rpm.
The time taken by the powers/granules (8 g of each formula-
tion) to rise over the surface of the medium (floating lag time)
and total floating time was measured visually (Mishra and
Dhole, 2019).
2.6. In vitro dissolution rate of gentiopicroside and floating
properties of the formulations
The dissolution tests were performed in triplicate using appa-
ratus type II (apparatus with rotating paddle, Erweka DT600,
Germany) with a paddle rotation speed of 50 rpm. Dissolution
medium consisted of 500 mL of 0.1 M HCl (pH=1.2) heated to
37 °C ± 0.5 °C. The weight of the powder/granules used for
the test was 8 g. The sample (4 mL) was taken after certain
time intervals and the medium was replenished after each
sampling. After filtration, the amount of dissolved gentiopi-
croside was analyzed by high pressure liquid chromatography
(HPLC).
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2.7. Determining the content of gentiopicroside by HPLC
Analyses were carried out on an Agilent 1200 RP HPLC instru-
ment, with diode array detector (DAD) and a reverse phase
Zorbax SB-C18 analytical column (150 mm × 4.6 mm; 5 µm
particle size) at a temperature of 25 °C according to the pre-
viously described method (Balijagić et al., 2012). The mobile
phase consisted of solvent A (1 % v/v, solution of orthophos-
phoric acid in water) and solvent B (acetonitrile) using an
gradient elution as follows: 0-5 min, 98-90 % A; 5-15 min, 90
% A; 15-20 min, 90-85 % A; 20-25 min, 85-70 % A; 25-30 min,
70-40 % A; 30-34 min, 40-0 % A. The injection volume was 5 µL.
Detection wavelengths were set at 260 nm and the flow rate
was 1 mL/min. The amounts of the dissolved gentiopicrosde
was calculated using calibration curve.
Table 1. Composition of prepared formulations
Formulation codes
A B C D E
Ingredients [%] [%] [%] [%] [%]
DGREa 25 25 25 25 25
HPMCb 15 15 15 15 -
Lactose, monohydrate 45 25 15 13 30
Effervescent componentsc 15 15 15 15 15
Compritol® 888 ATO - 20 30 30 30
Gelucire® 50/13 - - - 2 -
a DGRE - dry gentian root extract
b HPMC- hydroxypropyl methylcellulose
c Citric acid and sodium bicarbonate in the ratio of 0.76:1
3. RESULTS AND DISCUSSION
The flowability of the dry gentian root extract, and prepared
formulations, was determined by calculating Carr index and
Hausner ratio (Table 2). Dry gentian root extract has exhibited
poor flowability with Carr index of 28.99 % and Hausner ratio
of 1.41, which could be attributed to the sticky nature of the
extract. Furthermore, poor flowability of formulation A has
indicated that the addition of HPMC, lactose, and effervescent
compounds (sodium hydrogen carbonate and citric acid) to
gentian root extract has not enhanced flowability. Granules
with gentian root extract obtained by the hot-melt granulation
(formulations B, C, D and E) were characterized by improved
flowability (Carr index 14-22 %; Hausner ratio 1.16-1.28) in
comparison to the gentian root extract and formulation A.
Flowability of granules with the highest content of lipid ex-
cipients (formulation D) was superior to the flowability of
granules with lower content of lipid excipients. This result
has indicated that the hot-melt granulation has a positive in-
fluence on the flowability of gentian root extract and that the
addition of lipid excipients is related to the improved flowa-
bility. This finding is in accordance with a previous study
where the influence of hot-melt granulation on the flowability
of divalproex was investigated (Khaled et al., 2020).
Furthermore, lipid-based floating multiparticulate delivery
systems with berberine hydrochloride as active compound
and lipid carrier Gelucire® 43/01 as release retardant, HPMC
K4M as matrix polymer and sodium bicarbonate as a gas for-
mer were characterized with fair to good flowability (Mishra
and Dhole, 2019).
Table 2. Carr index and Hausner ratio of prepared formula-
tions and gentian root extract
Carr index Hausner ratio Flowability
[%]
DGREa 29 1.41 Poor
A 30 1.43 Poor
B 20 1.25 Fair
C 20 1.25 Fair
D 14 1.16 Good
E 16 1.19 Fair
a DGRE - dry gentian root extract
3.1. In vitro characterization of formulations
All investigated formulations have floated all the time during
the dissolution test. There was no floating lag time for any
formulations. This feature could be due to the lipophilic na-
ture and low density (0.46 g/mL) of Compritol®. The same
finding was reported when Compritol® was used to formulate
a self-emulsifying floating drug delivery system with tetrahy-
drocurcumin (Setthacheewakul et al., 2011). Furthermore, gas
(CO2) was formed by the reaction of a base (sodium bicar-
bonate) and acidic component (citric acid) of the formulation
in the presence of dissolution medium, while the density of
dosage forms decreased due to incorporation of generated gas
in HPMC matrix.
The influence of Compritol®, Gelucire® 50/13 and HPMC on
the gentiopicroside release behavior from the obtained floating
granules (formulations B,C,D and E) and powder (formulaton
A) was investigated. Release of gentiopicroside from formula-
tion A was rapid and more than 37.23 % of gentiopicroside was
dissolved in 1 h. On the other hand, a significant decrease in
the release rate of gentiopicroside was observed in the case of
granules obtained by the hot-melt granulation (formulations
B, C, D and E). It can be noticed that after the burst release of
gentiopicroside (21.98 %) in the first 30 min from formulation
A, in the second phase gentiopicrinoside release was slower.
It was reported previously that release from HPMC based gas-
tric floating drug delivery system appear to be bi-phasic with
initial burst effect (less than 30 min) followed by a polymer-
controlled slower release in the second phase (Li et al., 2003)),
while both diffusion and erosion mechanisms contribute to
the controlled release of active substances (Zhai et al., 2014).
By comparing the dissolution rates of formulations A and B
after 60 minutes, it is clear that the addition of Compritol® (20
%) has prevented the initial burst effect, and dissolution rate
of gentiopicroside was significantly decreased, due to the pro-
nounced hydrophobic nature of Compritol®, that facilitates
the sustained release of active compounds (Figure 1).
Khaled et al. (2020) have reported that Compritol® 888
ATO (glyceryl behenate) has enabled prolonged release of
divalproex and release was slower than in the case of
meltable binders such as Geleol® (glyceryl monostearate),
Precirol® ATO5 (glyceryl palmitostearate), and Gelucire®
50/13 (Stearoyl macrogol-32 glycerides). By comparing gen-
tiopicroside release from formulation B (28.61 %) and C (23.71
%) minor changes are noticed after 240 min, indicating that the
increase in the amount of Compritol® (from 20 % to 30 %) has
a negligible effect on dissolution rate. Formulation D with a
mixture of meltable binders (Gelucire® 50/13 and Compritol®)
was characterized with increased gentiopicroside release rate
in comparison to formulation C with Compritol®, as meltable
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Fig. 1. Getiopicroside release profile from formulation A and B
binder (Figure 2). This result is in accordance with the study
of Zhai et al. (2014) where it was noticed that metronidazole
release rate was increased, after the addition of Gelucire®
50/13 (2-4 %), as a bioavailability and solubility enhancer, to
the formulation of gastroretentive extended-release floating
granules, while addition of higher concentration (10-15 %)
Gelucire® 50/13 resulted in loss of sustained release. The
effect of HPMC on the release was evident when the percent-
age of dissolved gentiopicroside from formulation C (50.95
%) and E (100.46 %) after 8 h were compared. Gentiopicro-
side release from formulation E was characterized as bi-phasic
with initial slower release and faster release in the second
phase. The increased release rate in the second phase could be
a consequence of increased diffusion of dissolution medium
in floating granules without HPMC, due to the absence of
gelatinous layer formed in contact of hydrophilic polymer and
dissolution medium. A control over gentiopicroside release
rate is necessary, in order to avoid incomplete release that can
occur in the case of lipid-based delivery systems (Knežević
et al., 2009).
CONCLUSION
In this study, the hot-melt granulation technique, as a green
granulation method was successfully employed for obtain-
ing gastroretentive floating granules with gentian root extract.
The obtained floating granules were characterized with im-
proved flowability, immediate and long-lasting floating and
prolonged-release (over 8 h) of gentiopicroside, as a marker
compound in the gentian root extract. Compritol® 888 ATO
(20-30 %) used as a meltable binder has provided sustained re-
lease of gentiopicroside from floating granules, while HPMC
(15 %) as a hydrophilic polymer has decreased release rate
additionally. On the other hand, Gelucire® 50/13 (2 %) has
increased release rate of gentiopicroside. Therefore, gastrore-
tentive floating granules with Compritol® 888 ATO and addi-
tion of Gelucire® 50/13 and HPMC could be used for targeted
and sustained release of gentian root extract in the stomach.
Further development, optimization and in vitro and in vivo
evaluation of prepared floating systems could contribute to
gentian root extract efficiency, in terms of reduced dosing
frequency and ease of formulated product administration.
Fig. 2. Gentiopicroside release profile from formulations C, D and E
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